One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Top-down Versus Step-up Strategies to Prevent Postoperative Recurrence in Crohn’s Disease
Anthony Buisson, MD, PhD, Lysa Blanco, MSc, Luc Manlay, MD, Maud Reymond, MD, Michel Dapoigny, MD, PhD, Olivier Rouquette, MD, Anne Dubois, MD, Bruno Pereira, PhD
doi : 10.1093/ibd/izac065
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 185–194
The best management after ileocolonic resection is still unknown in Crohn’s disease (CD). We compared step-up and top-down approaches to prevent short and long-term postoperative recurrences in CD patients.
Molecular and Functional Characterization of Human Intestinal Organoids and Monolayers for Modeling Epithelial Barrier
Scott A Jelinsky, PhD, Merel Derksen, MSc, Eric Bauman, BSc, Carla S Verissimo, PhD, Wies T M van Dooremalen, MSc, Jamie Lee Roos, BSc, Celia Higuera Barón, MSc, Celia Caballero-Franco, PhD, Bryce G Johnson, MSc, Michelle G Rooks, PhD, Johanna Pott, PhD, Bas Oldenburg, MD, PhD, Robert G J Vries, PhD, Sylvia F Boj, PhD, Marion T Kasaian, PhD, Farzin Pourfarzad, PhD, Charles V Rosadini, PhD
doi : 10.1093/ibd/izac212
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 195–206
Patient-derived organoid (PDO) models offer potential to transform drug discovery for inflammatory bowel disease (IBD) but are limited by inconsistencies with differentiation and functional characterization.
Prevalence of and Factors Associated with Respiratory Symptoms Among Patients with Inflammatory Bowel Disease: A Prospective Study
Simon Valentin, MD, Brian Renel, MD, Florian Manneville, MD, Bénédicte Caron, MD, Myriam Choukour, MSc, Anne Guillaumot, MD, Ari Chaouat, PhD, Mathias Poussel, PhD, Thomas Chateau, MD, Carina Peyrin-Biroulet, MD, Hamza Achit, MD, Laurent Peyrin-Biroulet, PhD, François Chabot, PhD
doi : 10.1093/ibd/izac062
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 207–216
No large, prospective study has investigated respiratory symptoms in patients with inflammatory bowel diseases. We aimed to describe the prevalence of and factors associated with respiratory symptoms in patients with inflammatory bowel disease.
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19
Fabio Salvatore Macaluso, MD, Alessandra Giuliano, MD, Walter Fries,, Anna Viola, MD, Alfredo Abbruzzese, MD, Maria Cappello, MD, Enrica Giuffrida, MD, Lucio Carrozza, MD, Antonino Carlo Privitera, MD, Antonio Magnano, MD, Concetta Ferracane, MD, Giuseppe Scalisi, MD, Maria Giovanna Minissale, MD, Emiliano Giangreco, MD, Serena Garufi, MD, Carmelo Bertolami, MD, Ugo Cucinotta, MD, Francesco Graziano, MD, Angelo Casà , MD, Sara Renna, MD, PhD, Giulia Teresi, MD, Giulia Rizzuto, MD, Mariella Mannino, MD, Marcello Maida, MD, Ambrogio Orlando, MD Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
doi : 10.1093/ibd/izac064
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 217–221
Data from the first wave of the coronavirus disease 2019 (COVID-19) pandemic suggested that patients with inflammatory bowel disease (IBD) are not at higher risk of being infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than the general population and that a worse prognosis is not associated with immunomodulatory drugs, with the possible exception of systemic steroids.
Assessment of the Degree of Variation of Histologic Inflammation in Ulcerative Colitis
Adam E Mikolajczyk, MD, Nathaniel A Cohen, MD, Sydeaka Watson, PhD, Max Ackerman, Sarah R Goeppinger, John Hart, MD, Jerrold R Turner, MD, PhD, David T Rubin, MD
doi : 10.1093/ibd/izac070
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 222–227
Treatment of ulcerative colitis (UC) now includes mucosal healing. Adoption of histologic end points is hindered by a lack of evidence guiding optimal sampling, interpretation, and reproducibility of results.
Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry
Eirini Zacharopoulou, MD, PhD, Eleni Orfanoudaki, MD, PhD, Maria Tzouvala, MD, PhD, George Tribonias, MD, PhD, Georgios Kokkotis, MD, MSc, Vassiliki Kitsou, MD, Foteini Almpani, MD, Aggeliki Christidou, MD, Nikolaos Viazis, MD, PhD, Gerassimos J Mantzaris, MD, PhD, Maria Tsafaridou, MD, Konstantinos Karmiris, MD, PhD, Angeliki Theodoropoulou, MD, Evgenia Papathanasiou, MD, Evanthia Zampeli, MD, PhD, Spyridon Michopoulos, MD, PhD, Stefanos Tigkas, MD, Georgios Michalopoulos, MD, PhD, Efrossini Laoudi, MD, Pantelis Karatzas, MD, PhD, Iordanis Mylonas, MD, Nikolaos Kyriakos, MD, PhD, Christos Liatsos, MD, PhD, Theodora Kafetzi, MD, Georgios Theocharis, MD, Styliani Taka, PhD, Konstantina Panagiotopoulou, BSc, Ioannis E Koutroubakis, MD, PhD, Giorgos Bamias, MD, PhD
doi : 10.1093/ibd/izac068
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 228–237
Four EMA-approved vaccines against SARS-CoV-2 are currently available. Data regarding antibody responses to initial vaccination regimens in patients with inflammatory bowel diseases (IBD) are limited.
Histologic Activity and Steroid Use History Are Risk Factors of Clinical Relapse in Ulcerative Colitis With Mayo Endoscopic Subscore of 0 or 1
Gyeol Seong, MD, Joo Hye Song, MD, PhD, Ji Eun Kim, MD, Tae Jun Kim, MD, PhD, Eun Ran Kim, MD, PhD, Sung Noh Hong, MD, PhD, Dong Kyung Chang, MD, PhD, Seok-Hyung Kim, MD, PhD, Sang Yun Ha, MD, PhD, Young-Ho Kim, MD, PhD
doi : 10.1093/ibd/izac075
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 238–244
The treatment goal of ulcerative colitis (UC) has changed from the control of symptoms to mucosal healing, previously evaluated mainly by endoscopy. Recently, the importance of histologic activity has emerged. Therefore, this study aimed to investigate the risk of clinical relapse according to histologic activity in UC with a Mayo endoscopic subsccore (MES) of 0 or 1.
Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn’s Disease
Tatsuya Kawamura, MD, Takeshi Yamamura, MD, PhD, Masanao Nakamura, MD, PhD, Keiko Maeda, MD, PhD, Tsunaki Sawada, MD, PhD, Eri Ishikawa, MD, PhD, Tadashi Iida, MD, PhD, Yasuyuki Mizutani, MD, PhD, Takuya Ishikawa, MD, PhD, Naomi Kakushima, MD, PhD, Kazuhiro Furukawa, MD, PhD, Eizaburo Ohno, MD, PhD, Takashi Honda, MD, PhD, Hiroki Kawashima, MD, PhD, Masatoshi Ishigami, MD, PhD
doi : 10.1093/ibd/izac076
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 245–253
Mucosal healing, confirmed by endoscopic evaluation, is the long-term goal of treatment for Crohn’s disease (CD). Leucine-rich alpha-2 glycoprotein (LRG) is a new serum biomarker correlated with disease activity in inflammatory bowel disease.
Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease
Joshua Y Kwon, MD, Nader D Daoud, MD, Jana G Hashash, MD, MSc, Michael F Picco, MD, PhD, Francis A Farraye, MD, MSc
doi : 10.1093/ibd/izac079
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 254–259
Owing to the use of immunosuppressive agents, patients with inflammatory bowel disease (IBD) have an increased risk of vaccine preventable diseases, including infection with hepatitis B virus (HBV).
Increased Risk of Postpartum Infections After Caesarian and Vaginal Delivery in Women With Inflammatory Bowel Disease: A Danish Nationwide Cohort Study
Sonia Friedman, MD, Floor Dijkstra Zegers, MSc, Line Riis Jølving, PhD, Jan Nielsen, PhD, Bente Mertz Nørgård, MD, PhD, DMSc
doi : 10.1093/ibd/izac088
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 260–267
There is lack of knowledge concerning postpartum infections in women with inflammatory bowel disease (IBD). Our aim is to determine the 30-day postpartum infectious complications in women with and without IBD who have a caesarian section, normal vaginal delivery, or assisted vaginal delivery.
Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
VÃtor Macedo Silva, MD, Tiago Lima Capela, MD, Marta Freitas, MD, Tiago Cúrdia Gonçalves, MD, Pedro Boal Carvalho, MD, Francisca Dias de Castro, MD, Maria João Moreira, MD, José Cotter, MD, PhD
doi : 10.1093/ibd/izac187
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 268–273
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may lead to the development of the novel coronavirus disease (coronavirus disease 2019 [COVID-19]).
Assessing Cellular and Transcriptional Diversity of Ileal Mucosa Among Treatment-Naïve and Treated Crohn’s Disease
Sushma Chowdary Maddipatla, MS, Vasantha L Kolachala, PhD, Suresh Venkateswaran, PhD, Anne F Dodd, BS, Ranjit Singh Pelia, MPH, Duke Geem, MD, PhD, Hong Yin, MD, Yutong Sun, MS, Congmin Xu, PhD, Angela Mo, PhD, Astrid Kosters, PhD, Junkai Yang, MS, Jason D Matthews, PhD, Eliver Ghosn, PhD, Subra Kugathasan, MD, Peng Qiu, PhD
doi : 10.1093/ibd/izac201
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 274–285
Crohn’s disease is a lifelong disease characterized by chronic inflammation of the gastrointestinal tract. Defining the cellular and transcriptional composition of the mucosa at different stages of disease progression is needed for personalized therapy in Crohn’s.
Patient-Reported Outcomes Correlate With Microbial Community Composition Independent of Mucosal Inflammation in Pediatric Inflammatory Bowel Disease
Jennifer Hellmann, MD, Allison Ta, MD, MS, Nicholas J Ollberding, PhD, Ramona Bezold, BSN, Kathleen Lake, BA, MSW, Kimberly Jackson, BA, Kelsie Dirksing, PA, Erin Bonkowski, BA, David B Haslam, MD, Lee A Denson, MD
doi : 10.1093/ibd/izac175
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 286–296
Inflammatory bowel diseases (IBDs) involve an aberrant host response to intestinal microbiota causing mucosal inflammation and gastrointestinal symptoms.
The Current State of Care for Black and Hispanic Inflammatory Bowel Disease Patients
Julia J Liu, MD, MSc, Bincy P Abraham, MD, MS, Paula Adamson, MD, Edward L Barnes, MD, MPH, Kelly A Brister, MD, Oriana M Damas, MD, Sarah C Glover, DO, Kimberly Hooks, BA, Ana Ingram, MA, Gilaad G Kaplan, MD, MPH, Edward V Loftus, Jr., MD, Dermot P B McGovern, MD, PhD, Melodie Narain-Blackwell, BA, Florence-Damilola Odufalu, MD, Sandra Quezada, MD, MS, Vonda Reeves, MD, Bo Shen, MD, Thaddeus S Stappenbeck, MD, PhD, Latonia Ward, MM
doi : 10.1093/ibd/izac124
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 297–307
Research on the care of inflammatory bowel disease (IBD) patients has been primarily in populations of European ancestry. However, the incidence of IBD, which comprises Crohn’s disease and ulcerative colitis, is increasing in different populations around the world.
MiRNA-Based Therapies for the Treatment of Inflammatory Bowel Disease: What Are We Still Missing?
Tommaso Innocenti, MD, Elisabetta Bigagli, PhD, Erica Nicola Lynch, MD, Andrea Galli, MD, PhD, Gabriele Dragoni, MD
doi : 10.1093/ibd/izac122
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 308–323
Micro-RNAs (miRNAs) are noncoding RNAs usually 24-30 nucleotides long that play a central role in epigenetic mechanisms of inflammatory diseases and cancers.
Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials
Rocio Sedano, MD, Malcolm Hogan, MSc, Guangyong Zou, PhD, Neeraj Narula, MD, Siddharth Singh, MD, Christopher Ma, MD, Brian G Feagan, MD, Vipul Jairath, MD, PhD
doi : 10.1093/ibd/izac128
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 324–327
Environmental Interaction of Resolved Human Cytomegalovirus Infection With Crohn’s Disease Location
Terri Shih, BS, Susy Yusung, MD, Rivkah Gonsky, PhD, Rhiannon Dutra-Clarke, BS, David Ziring, MD, Shervin Rabizadeh, MD, MBA, Subra Kugathasan, MD, Lee A Denson, MD, Dalin Li, PhD, Jonathan Braun, MD, PhD
doi : 10.1093/ibd/izac251
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 328–331
Deep Remission in Severe Refractory Crohn’s Disease With Mycophenolate Mofetil
Jeffrey Jacobs, MD, Kindra Clark-Snustad, DNP, Scott Lee, MD
doi : 10.1093/ibd/izac213
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 332–333
Single-cell Transcriptomics Reveal the Importance of Distinct Epithelial Cell Populations in Ileal-specific, Treatment-naïve, and Treated Crohn’s Disease Patients
Daniele Corridoni, PhD, Theresa T Pizarro, PhD
doi : 10.1093/ibd/izac264
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 334–336
Correction to: The Impact of Disease Activity on SD and ED in Patients With Inflammatory Bowel Disease
doi : 10.1093/ibd/izac258
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Page 337
Novel Patient-centered Educational Panel Enhances Preclinical Medical Student Understanding of IBD Beyond What Can Be Learned in a Traditional Classroom
Jamie Horrigan, MD, Micheal Tadros, MD, MPH
doi : 10.1093/ibd/izac239
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages e3–e4
